Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

Tvardi Therapeutics (NASDAQ: TVRD) will present at Chardan’s 10th Annual Healthcare Conference in New York City on October 20, 2026.

Rhea-AI Summary

Tvardi Therapeutics (NASDAQ: TVRD) will present at Chardan’s 10th Annual Healthcare Conference in New York City on October 20, 2026.

The presentation is scheduled for 1:30 PM ET. Members of the management team will also be available to meet with investors registered to attend the conference.

Key Terms

stat3, phase 1b/2 clinical trial, hepatocellular carcinoma

3 terms

stat3 technical

"therapies targeting STAT3 to treat inflammatory and proliferative diseases"

STAT3 is a protein inside cells that acts like a control knob for turning sets of genes on or off, influencing cell growth, survival and immune responses. For investors, STAT3 matters because drugs or tests that block or measure its activity can be used to treat or track cancers and inflammatory diseases, so progress on STAT3-targeted therapies or diagnostics can affect the value and prospects of biotech and pharmaceutical firms.

phase 1b/2 clinical trial medical

"conducting a Phase 1b/2 clinical trial"

A phase 1b/2 clinical trial is an early-stage human study that combines the objectives of a phase 1b trial (refining dose, schedule and initial safety or tolerability in a target patient population) with those of a phase 2 trial (preliminary assessment of whether the treatment has the intended biological effect or clinical benefit). It typically enrolls more patients than a pure phase 1 study, may use adaptive or separate cohorts to find a recommended dose, and measures safety plus early efficacy signals using predefined endpoints, but it is not designed to provide definitive proof of efficacy or long-term safety.

hepatocellular carcinoma medical

"TTI-101 in hepatocellular carcinoma"

Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10^th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.

Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in gastrointestinal (GI) diseases pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com